Mizuho Adjusts Price Target#
Mizuho has lowered its price target for Universal Health Services (NYSE: UHS) from $267 to $230 while keeping an Outperform rating. This adjustment reflects concerns about seasonal challenges that have impacted the company’s earnings.
Impact of Seasonal Headwinds#
The firm revised its adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) estimates for 2026-2028 down by 2%. This change accounts for negative seasonal factors that were not included in previous estimates. Following the release of first-quarter results for 2026, the stock dropped by 9%, falling to $162.54 and nearing its 52-week low of $152.33.
Earnings and Valuation Insights#
Mizuho noted that the base adjusted EBITDA, excluding certain factors like Medicaid and weather impacts, declined by 3%. Hospitals typically increase staffing during flu season, and the firm believes that the inability to reduce staffing quickly enough may have negatively affected earnings. Despite these challenges, Mizuho argues that the recent stock sell-off is excessive and maintains its Outperform rating.
Recent Performance and Analyst Sentiment#
In its latest earnings report, Universal Health Services posted adjusted earnings per share of $5.62, surpassing analyst expectations of $5.41. Revenue also exceeded forecasts at $4.49 billion, compared to the anticipated $4.39 billion. However, the company expressed concerns over ongoing pressures from health insurance exchange trends, which have caused investor anxiety. Following these developments, TD Cowen also lowered its price target for the company from $245 to $230, while still maintaining a Buy rating. This situation reflects a mixed sentiment among analysts and investors regarding the future performance of Universal Health Services.